Minimizing the toxicity of aminoglycosides in cystic fibrosis.
Smyth
Alan R
AR
Division of Human Development (Child Health), School of Clinical Sciences, E floor East Block, Queens Medical Centre, Nottingham NG7 2UH, UK. alan.smyth@nottingham.ac.uk
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000517:prevention & control; D000617:Aminoglycosides / Q000008:administration & dosage / Q000009:adverse effects*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000150:complications*; D004272:DNA, Mitochondrial / Q000235:genetics; D004334:Drug Administration Schedule; D020022:Genetic Predisposition to Disease; D005839:Gentamicins / Q000008:administration & dosage / Q000009:adverse effects; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced / Q000235:genetics / Q000517:prevention & control; D006801:Humans; D009154:Mutation; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa; D051437:Renal Insufficiency / Q000139:chemically induced / Q000517:prevention & control; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D004272:DNA, Mitochondrial; D005839:Gentamicins; D014031:Tobramycin